Yes

Keep It Simple, Stupid.

不同影响因子用的数据分析软件

Posted at — Aug 12, 2021

影响因子|杂志|统计软件|年|文章名|数据可信度 – | – | – | – | – | –
4.100|Int J Mol Med|GraphPad Prism 5|2020|MyD88 mediates colorectal cancer cell proliferation, migration and invasion via NF‑κB/AP‑1 signaling pathway 22.112|Blood|R|2014|Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia 7.563|Front Immunol|GraphPad Prism 8|2020|Modeling MyD88 Deficiency In Vitro Provides New Insights in Its Function 12.910|J Cachexia Sarcopenia Muscle|GraphPad Prism 5.0|2019|MyD88 signalling is critical in the development of pancreatic cancer cachexia 22.113|Blood Clinical Trial|Prism |2014|IRAK-4 and MyD88 deficiencies impair IgM responses against T-independent bacterial antigens 5.153|J Biol Chem| SigmaStat 3.1\Systat 软件|2002|Regulation of reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation 49.960|Nature| FASCDiva software version 8.0.2 to collect and analyze the flow cytometry data.|2018|Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance |Data Availability Statement (DAS)数据可用性声明 (DAS) 27.401|review>Mol Cancer||2020|The emerging role of SPOP protein in tumorigenesis and cancer therapy |Data Availability Statement 27.404|Mol Cancer|GraphPad Prism|2019|Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembl|Data Availability Statement |17.971|Mol Cell|GraphPad Prism |2018|Cancer Mutations of the Tumor Suppressor SPOP Disrupt the Formation of Active, Phase-Separated Compartment 14.432|Review>Nat Rev Urol||2020|The diverse roles of SPOP in prostate cancer and kidney cancer 12.530|Clin Cancer Res|Stata v13.1 |2018|SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity 11.523|Leukemia| |2020|CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling 17.364|Review>Circ Res|使用最新的生物信息学集成方法 Harmony86 分析了来自 9 个数据集(在线数据集)的 scRNA-Seq 数据,使用非线性高维推导方法 UMAP(Uniform Manifold Approximation and Projection)87 可视化所有细胞|2020 |Meta-Analysis of Leukocyte Diversity in Atherosclerotic Mouse Aortas 24.632|Cell Stem Cell|文章太新没有全文|2021 |Establishment, maintenance, and recall of inflammatory memory 49.961|Clinical Trial>Nature||2014 |Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients 44.542|Clinical Trial >J Clin Oncol|Kaplan-Meier method评估反应持续时间、无进展生存期和总生存期|2020 |Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study 32.973|Clinical Trial>Ann Oncol|The Kaplan-Meier (KM) method |2019 |Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 44.542|Randomized Controlled Trial>J Clin Oncol|the Kaplan-Meiermethod.|2020 |Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study 31.772|Meta-Analysis>JAMA Oncol|the Kaplan-Meier method|2015 |Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials 56.270|Clinical Trial>JAMA|SAS 软件 9.3 版.客观缓解率和相关的 95% CI 是使用 Clopper-Pearson 方法估算的,使用 Kaplan-Meier 方法估计无进展生存期、总生存期和生存率|2016|Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma 44.541|J Clin Oncol| SAS 软件|2017 |Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma 91.244|Randomized Controlled Trial>N Engl J Med|SAS software (version 9; SASInstitute, Cary, NC)|2019 |Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma 47.723|Science||2017 |Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages 8.142|EBioMedicine|GraphPad™Prism软件 |2019 |IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states 14.803|Clinical Trial>J Clin Invest|NanoString 平台|2017 |IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade 47.723|Science| Matlab R 2010 或 R 3.4.1 进行统计分析和可视化|2018 |Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy 8.112|Oncoimmunology|RevMan 5.3|2019 |High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients 3.934|Ann Transl Med|R v. 3.5.1|2019 |Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers 44.543|Clinical Trial>J Clin Oncol|Kaplan-Meier 方法|2016 |Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma 12.532|Multicenter Study>Clin Cancer Res|STATA V11 software|2014 |Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy -|Nano Today|Kaplan-Meier 方法确定每组的生存数据的显着性分析,并通过对数秩 (Mantel-Cox) 检验进行比较|2021|Recombinant cancer nanovaccine for targeting tumor-associated macrophage and remodeling tumor microenvironment 14.911|Nat Commun|Kaplan-Meier 对数秩检验分析生存数据。| 2015 |Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints 0.871 | 中国实验诊断学|GraphPADPrism6.0进行单因素方差分析|2021|D-缬氨酸抑制巨噬细胞M1极化的体外研究 2.67|食品科学|spss19.0|2021|水溶性豆渣酸性糖对RAW264.7细胞的免疫调节作用及其机制 1.281|现代药物与临床|spss21.0|2021|速感宁胶囊联合磷酸奥司他韦治疗流行性感冒的疗效及其对血清炎性因子的影响